Sapan A. Shah

About

Sapan A. Shah, Ph.D., is a biotechnology executive serving as CEO of Glyscend Therapeutics, a venture-backed clinical-stage company developing gut-targeted therapies for type 2 diabetes and obesity. Glyscend's 2023 appointment announcement says he previously served as CEO of StrideBio, ARMGO Pharma, Ezose Sciences, and Shionogi Inc., and earlier worked as a consultant at McKinsey & Company. A 2009 Shionogi annual report identifies him as CEO of Shionogi USA, reflecting a long operating career in biopharma company building, development, and commercialization.

Areas of interest